Navigation Links
China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
Date:5/4/2012

HAIKOU CITY, China, May 4, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it plans to release its first quarter of year 2012 financial results before the market opens on Tuesday, May 15, 2012.

The Company will hold a conference call at 8:30 am ET on May 15, 2012 to discuss first quarter of year 2012 results. Listeners may access the call by dialing 1-866-519-4004 or 65-672-393-81 for international callers, Conference ID # 78450563. A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com. A replay of the call will be accessible through May 22, 2012 by dialing 1-866-214-5335 or 61-282-355-000 for international callers, Conference ID # 78450563.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com.

Contact:

China Pharma Holdings, Inc.
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Biologic Has Announced the Resignation of CFO Y. Tristan Kuo and Named Mr. Ming Yang as Interim CFO
2. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR
3. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
4. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
5. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
6. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
7. 3SBio Inc. to Present at the UBS Greater China Conference 2012
8. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
11. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  Creative Medical Technology ... , MD, PhD, FANA, FAAN to the Company,s Scientific ... and clinical trials to assist the Company,s clinical development ... AmnioStem product is a universal donor stem cell derived ... in animal models of stroke 1 .  ...
(Date:12/6/2016)... ... December 06, 2016 , ... ProMIS ... of precision treatments for neurodegenerative diseases, today announced the validated monoclonal antibody ... direct neurotoxic effect of prion-like forms of Amyloid beta (Aß) in vitro. ...
(Date:12/5/2016)... 5, 2016 Research and Markets has ... Technologies, Markets and Companies" to their offering. ... , , ... using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics ... are also based on biomarker. Currently the most important ...
(Date:12/5/2016)... DIEGO , Dec. 5, 2016  Renova™ ... for congestive heart failure and other chronic diseases, ... joining the company as Chief Financial Officer (CFO), ... Therapeutics with 20 years of experience in financial ... held biotech and software companies. Most recently, Ms. ...
Breaking Biology Technology:
(Date:11/22/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the company has ... Sciences Awards as "Most Outstanding in eClinical Solutions" ... of recognition and growth for MedNet, which has effectively ... iMedNet ™ , MedNet,s flagship eClinical ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):